Seattle Genetics, Pieris partner for immuno-oncology

Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) partnered to develop bispecific

Read the full 168 word article

User Sign In